You are here

Long-Acting IL-11 for Treating Thrombocytopenia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44CA084851-02
Agency Tracking Number: CA084851
Amount: $0.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BOLDER BIOTECHNOLOGY, INC. 4056 YOUNGFIELD ST
WHEAT RIDGE, CO 80033
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DANIEL DOHERTY
 (303) 420-4420
 DDOHERTY@BOLDERBIO.COM
Business Contact
 GEORGE COX
Phone: (303) 420-4420
Email: JCOX@BOLDERBIO.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Interleukin 11 (IL-11) is a cytokine that stimulates proliferation, maturation and functional activation of platelets. Recombinant human IL- 11 is approved and marketed as a treatment for thrombocytopenia in certain patients undergoing myelosuppressive cancer chemotherapy, the market for which is estimated to be $500 million. IL-11 has a short in vivo half-life and must be administered daily by subcutaneous injection to achieve optimal efficacy. The investigators propose to create modified IL-11 proteins that are equal, or superior, to natural IL- 11 at stimulating platelet formation in vivo, but which require less frequent dosing, on the order of once per week to once every third week. During Phase I the investigators identified sites in IL- 11 that can be modified without affecting the protein's in vitro bioactivity. During Phase II, sufficient quantities of the modified IL-11 proteins will be manufactured for testing of pharmacokinetics and efficacy in normal rodents and in rodent models of chemically induced thrombocytopenia. In the clinical setting, the improved properties of the novel IL-11 proteins will reduce the amount of IL-11 required per patient, improve patient compliance, and result in considerable cost savings to patients and healthcare providers. Additional potential benefits include improved drug efficacy, ease of use and improved patient quality of life. Information gained from these studies will aid in creating long-acting versions of structurally related cytokines and growth factors for use in treating cancer, infectious disease and hematopoietic disorders

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government